Precision medicine is facilitating doctors to choose treatment methods based on a genetic understanding of diseases, ultimately enhancing patient care.
FREMONT, CA: A pioneering precision medicine intelligence company, Amplion has launched Dx:Revenue, a software solution facilitating test providers to identify ideal pharmaceutical partnership opportunities at the appropriate time to advance precision medicine partnership. Dx:Revenue is an expansion of Amplion's core business intelligence platform, leveraging proprietary Machine Learning (ML) to deliver tailored insights for test developers and pharma activities. Dx: Revenue's platform attracts from more than 34 million evidence sources such as conference abstracts, clinical trials, scientific publications, FDA cleared and approved tests, and more in real-time, producing prioritized and convenient partnering opportunities. Such opportunities are a definite match between a test provider's abilities and pharma's specific needs.
The rising adoption of precision medicine for patient care enables doctors to select a therapy based on the underlying biological drivers of a patient's condition, thereby improving health results drastically. Before the launch of Dx:Revenue, drug, and test developers created innovative treatments, forced to comb via millions of uncategorized publications in quest of appropriate drug and clinical development and biomarker activity. Amplion applies advanced ML models to the entire biomedical landscape to classify opportunities that match test developers' capabilities and needs precisely. The company's proprietary models understand the context within which a medical term is being used, enabling test developers to initiate research and development effectively.
Amplion is a business intelligence platform that leverages proprietary ML and biomedical domain expertise to speed up precision medicine. The company focuses on advancing the principal drivers of precision medicine, empowering companies to zero in on the market and research components, turning precision medicine into a reality. Amplion offers evidence-based biomarker intelligence that supports the essential strategic decisions that the diagnostic and pharmaceutical developers require to prosper in the upcoming era of precision medicine. Amplion's mission is to save lives and enhance patient care using precision medicine.